Sitagliptin Phosphate is the main active component in this medication. It is the beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) that has hypoglycemic activity. This medication may cause an increased risk of the development of pancreatitis. This active ingredient increases the levels of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. It is used in the treatment of type 2 diabetes.
Sitagliptin Phosphate composed medicine is indicated with a proper diet and exercise program to control high blood sugar. This drug is approved for people with type 2 diabetes. Lowering high blood sugar prevents kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It also lowers the risk of a heart attack or stroke.
Januvia is a diabetes drug that increases levels of natural substances called incretins. Incretins help to control blood sugar by maximizing insulin release after a meal. It also reduces the amount of sugar the liver produces.
- Upper Respiratory Tract Infection
This mentioned medication is a DPP-4 inhibitor drug that works by increasing the amount of incretin released by the intestine. Incretin is a hormone that increases insulin levels when blood sugar is high. Januvia reduces the amount of sugar produced by the body.
This dipeptidyl peptidase medicine is available in a dosage as given below:
- 25 mg: Consume this medicine once a day with or without food, as directed by the doctor
- 50 mg: It is to be consumed once a day as prescribed by the doctor
Stop taking Januvia and call your doctor if you have symptoms of pancreatitis: severe pain in your upper stomach spreading to your back, with or without vomiting.